The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
 
Shui-Ling Jin
No Relationships to Disclose
 
Shishi Qiao
No Relationships to Disclose
 
Ren-Feng Li
No Relationships to Disclose
 
Weijie Zhang
No Relationships to Disclose
 
Wei He
No Relationships to Disclose
 
Chang Su
No Relationships to Disclose
 
Lu-Hao Li
No Relationships to Disclose
 
Jie Pan
No Relationships to Disclose
 
Wen-Zhi Guo
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose